export default function SurvodutideOverviewPanel() {
  return (
    <div className="reta-overview">
      <p className="reta-overview__lead">
        Survodutide is a dual agonist of the GLP-1 receptor (GLP-1R) and the glucagon receptor
        (GCGR) \u2014 developed by Boehringer Ingelheim and Zealand Pharma. It is investigational as of
        early 2026: not FDA-approved, not commercially available, but generating some of the most
        interesting metabolic data in the current pipeline.
      </p>
      <p>
        The dual-receptor strategy is deliberate. GLP-1 receptor agonism drives the familiar
        mechanisms: appetite suppression, slowed gastric emptying, improved insulin secretion,
        reduced glucagon in hyperglycemic states. Glucagon receptor agonism adds a second metabolic
        lever: glucagon increases energy expenditure, promotes lipolysis in fat tissue, and has
        potent effects on hepatic lipid metabolism \u2014 specifically, it drives fatty acid
        oxidation and reduces hepatic fat accumulation. The combination is designed to deliver
        weight loss beyond what pure GLP-1 agonism achieves, while simultaneously targeting the
        liver in a way that semaglutide and tirzepatide do only secondarily.
      </p>
      <p>
        In phase 2 trials, survodutide produced weight loss in the range of 14\u201319% of body
        weight at 46 weeks \u2014 comparable to semaglutide 2.4 mg and overlapping with tirzepatide\u2019s
        range, though head-to-head comparisons don\u2019t yet exist in the peer-reviewed literature.
        More distinct is the liver signal: the MASH (metabolic dysfunction-associated
        steatohepatitis) data from the phase 2 NASH program showed meaningful reductions in liver
        fat fraction and histological markers of steatohepatitis, elevating survodutide as a
        candidate in a disease space where few approved drugs exist.
      </p>
      <p>
        Phase 3 trials \u2014 the SYNCHRONIZE program for obesity and a separate MASH-focused
        program \u2014 were underway as of 2025\u20132026. The MASH results in particular have attracted
        significant clinical attention because the liver histology improvements in phase 2 exceeded
        what most GLP-1 monotherapy trials have shown, suggesting that the glucagon arm is doing
        meaningful work beyond appetite suppression.
      </p>
      <p>
        The trade-off for stronger efficacy is the side-effect profile. The glucagon receptor
        component adds a hyperglycemia risk \u2014 glucagon is glycogenolytic and gluconeogenic \u2014 that
        is absent or minimal with pure GLP-1 agonists. In metabolic syndrome patients this is
        generally offset by the concurrent GLP-1-mediated insulin augmentation, but it is a
        pharmacological risk that is managed differently than with GLP-1 monotherapy. GI side
        effects (nausea, vomiting, diarrhea) are at least as prevalent as with semaglutide and
        may be more pronounced at higher doses.
      </p>
      <p>
        Where survodutide fits in the future landscape depends heavily on the phase 3 readouts,
        particularly for MASH. If the histology data hold at scale, it could become the first
        dual GLP-1R/GCGR drug to reach approval in that indication \u2014 a space with significant
        unmet medical need. For obesity alone, its competitive differentiation against retatrutide
        (triple agonist) and tirzepatide (GIP/GLP-1 dual) is less obvious.
      </p>
    </div>
  );
}
